Healthcare provider profile · identity verified

Anthony M. Fu, MD

Internal Medicine · ROSEVILLE, CA · NPI 1467530147

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	564	205
Amlodipine Besylate	Amlodipine Besylate	427	152
Losartan Potassium	Losartan Potassium	389	134
Levothyroxine Sodium	Levothyroxine Sodium	290	96
Lisinopril	Lisinopril	242	84
Albuterol Sulfate Hfa	Albuterol Sulfate	200	78
Tamsulosin Hcl	Tamsulosin Hcl	187	74
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	179	46
Furosemide	Furosemide	174	66
Metoprolol Succinate	Metoprolol Succinate	164	59
Fluticasone Propionate	Fluticasone Propionate	163	56
Gabapentin	Gabapentin	161	60
Trazodone Hcl	Trazodone Hcl	154	50
Tizanidine Hcl	Tizanidine Hcl	143	50
Atenolol	Atenolol	138	48
Metoprolol Tartrate	Metoprolol Tartrate	136	52
Meloxicam	Meloxicam	126	37
Pantoprazole Sodium	Pantoprazole Sodium	125	40
Potassium Chloride	Potassium Chloride	125	50
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	117	43
Omeprazole	Omeprazole	113	41
Famotidine	Famotidine	111	47
Jardiance	Empagliflozin	104	34
Metformin Hcl Er	Metformin Hcl	101	38
Hydralazine Hcl	Hydralazine Hcl	99	34
Ibuprofen	Ibuprofen	84	31
Alvesco	Ciclesonide	83	29
Pradaxa	Dabigatran Etexilate Mesylate	78	34
Clopidogrel	Clopidogrel Bisulfate	77	28
Alendronate Sodium	Alendronate Sodium	76	25
Tadalafil	Tadalafil	75	21
Triamcinolone Acetonide	Triamcinolone Acetonide	74	48
Wixela Inhub	Fluticasone Propion/Salmeterol	74	22
Terazosin Hcl	Terazosin Hcl	71	27
Rosuvastatin Calcium	Rosuvastatin Calcium	69	27
Metformin Hcl	Metformin Hcl	68	26
Montelukast Sodium	Montelukast Sodium	66	23
Nabumetone	Nabumetone	66	29
Prednisone	Prednisone	63	33
Glipizide	Glipizide	60	21
Fluoxetine Hcl	Fluoxetine Hcl	58	22
Ozempic	Semaglutide	58	14
Venlafaxine Hcl Er	Venlafaxine Hcl	58	21
Hydrochlorothiazide	Hydrochlorothiazide	57	23
Carvedilol	Carvedilol	55	21
Duloxetine Hcl	Duloxetine Hcl	53	23
Lovastatin	Lovastatin	53	19
Acyclovir	Acyclovir	52	18
Spironolactone	Spironolactone	51	18
Spiriva Respimat	Tiotropium Bromide	50	22
Doxycycline Monohydrate	Doxycycline Monohydrate	49	33
Propranolol Hcl	Propranolol Hcl	49	20
Cholestyramine	Cholestyramine (With Sugar)	44	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	44	12
Warfarin Sodium	Warfarin Sodium	44	19
Simvastatin	Simvastatin	43	17
Tramadol Hcl	Tramadol Hcl	42	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	41	35
Allopurinol	Allopurinol	39	17
Cephalexin	Cephalexin	39	24
Isosorbide Mononitrate Er	Isosorbide Mononitrate	39	suppressed
Ondansetron Hcl	Ondansetron Hcl	39	18
Sumatriptan Succinate	Sumatriptan Succinate	39	12
Buspirone Hcl	Buspirone Hcl	35	suppressed
Lorazepam	Lorazepam	34	17
Finasteride	Finasteride	33	13
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	31	suppressed
Eliquis	Apixaban	31	suppressed
Naproxen	Naproxen	30	suppressed
Ropinirole Hcl	Ropinirole Hcl	30	suppressed
Donepezil Hcl	Donepezil Hcl	29	11
Bupropion Xl	Bupropion Hcl	28	suppressed
Humulin N	Insulin Nph Human Isophane	28	11
Citalopram Hbr	Citalopram Hydrobromide	27	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	13
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	26	12
Cefadroxil	Cefadroxil	25	21
Colchicine	Colchicine	25	11
Metronidazole	Metronidazole	25	14
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Sertraline Hcl	Sertraline Hcl	24	11
Trospium Chloride	Trospium Chloride	24	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	23	23
Clobetasol Propionate	Clobetasol Propionate	23	12
Hydrocortisone	Hydrocortisone	22	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Amoxicillin	Amoxicillin	19	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	15
Estradiol	Estradiol	19	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	18	suppressed
Carbamazepine	Carbamazepine	17	suppressed
Nystatin	Nystatin	17	11
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Topiramate	Topiramate	16	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Nitroglycerin	Nitroglycerin	15	11
Rizatriptan	Rizatriptan Benzoate	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	14	suppressed
Fluconazole	Fluconazole	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Terbinafine Hcl	Terbinafine Hcl	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Fluorouracil	Fluorouracil	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Baclofen	Baclofen	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Lactulose	Lactulose	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Testosterone	Testosterone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error